Awaiting product image

General Medicine, Urology

Silimed 8

Contains: Silodosin 8 mg
Therapeutic Class: Selective α₁A-Adrenergic Receptor Antagonist
Schedule: Schedule H (Prescription Drug)

Silimed 8 contains Silodosin, a highly selective α₁A-adrenoceptor antagonist used in the treatment of Benign Prostatic Hyperplasia (BPH). It selectively blocks α₁A receptors located in the prostate, bladder neck, and urethra, resulting in smooth muscle relaxation, improved urinary flow, and relief of lower urinary tract symptoms (LUTS) associated with BPH.

Silodosin offers rapid onset of symptom relief, minimal cardiovascular effects due to its high uroselectivity, and excellent tolerability, making it a preferred agent among α-blockers.

Description

Usage of Silimed 8

Benign Prostatic Hyperplasia (BPH)
- To relieve symptoms such as:
  - Hesitancy
  - Weak stream
  - Incomplete bladder emptying
  - Nocturia
  - Urgency and frequency
May be used as monotherapy or in combination with 5-alpha reductase inhibitors

Common Side Effects

Retrograde ejaculation (common but reversible)
Dizziness or postural hypotension (less frequent due to uroselectivity)
Nasal congestion
Diarrhea or mild GI upset
Headache, fatigue (rare)

Retrograde ejaculation is dose-dependent and usually resolves upon discontinuation.

Precautions

Postural hypotension risk—use caution in patients with low baseline BP or on antihypertensives
Hepatic impairment: Use with caution
Severe renal impairment (CrCl <30 mL/min): Not recommended
Not for use in females or children
Cataract surgery: Risk of Intraoperative Floppy Iris Syndrome (IFIS)—inform ophthalmologist before surgery
Avoid alcohol while on treatment

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May increase silodosin levels—avoid co-administration
Antihypertensives: Additive hypotensive effect possible
Phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil): Use with caution—monitor for BP drop
Alpha-blockers: Do not combine with other α₁-blockers

Dosage and Administration

Silodosin 8 mg once daily, preferably with food to improve bioavailability and reduce adverse effects
Dose adjustment in moderate renal impairment (CrCl 30–50 mL/min): 4 mg once daily
Swallow whole; do not crush or chew

Storage

Store in a cool, dry place below 25°C
Protect from light and moisture

Patient Counselling Tips

Take the capsule with meals for best effect and tolerability
May cause dizziness—rise slowly from sitting or lying position
Inform about the possibility of retrograde ejaculation—this is harmless and reversible
Avoid driving or operating machinery if dizziness occurs
Inform eye surgeon before cataract surgery about Silodosin use
Do not discontinue medication abruptly without consulting your doctor